Celcuity Inc CELC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $14.24
- Day Range
- $14.24–14.61
- 52-Week Range
- $8.39–22.19
- Bid/Ask
- $5.76 / $17.07
- Market Cap
- $533.23 Mil
- Volume/Avg
- 101,975 / 392,085
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 55
- Website
- https://www.celcuity.com
Comparables
Valuation
|
Metric
|
CELC
|
ERAS
|
BMEA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.02 | 1.62 | 3.45 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CELC
|
ERAS
|
BMEA
|
|---|---|---|---|
Quick Ratio | 14.50 | 16.41 | 0.00 |
Current Ratio | 14.95 | 16.79 | 4.62 |
Interest Coverage | −13.28 | — | — |
Quick Ratio
CELC
ERAS
BMEA
Profitability
|
Metric
|
CELC
|
ERAS
|
BMEA
|
|---|---|---|---|
Return on Assets (Normalized) | −39.76% | −25.42% | −62.52% |
Return on Equity (Normalized) | −58.91% | −31.11% | −73.48% |
Return on Invested Capital (Normalized) | −44.39% | −31.15% | −74.59% |
Return on Assets
CELC
ERAS
BMEA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fnfrfvgy | Pxwxq | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hsxkqmpw | Synpqw | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gjydndtyk | Typzmpm | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zssztskg | Mkmgp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Jndyhlws | Zvhv | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Swnmgxxtd | Vnn | $28.1 Bil | |||
| Moderna Inc
MRNA
| Qkjppynk | Rmy | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Jbftcvyl | Wvsh | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dtwkhhck | Xypwjb | $13.4 Bil | |||
| Incyte Corp
INCY
| Zlzrwhlk | Bfhwks | $12.7 Bil |
United States